Incapacitating solar urticaria: successful treatment with omalizumab

AUTOR(ES)

Kieselova, Katarina

FONTE

An. Bras. Dermatol.

DATA DE PUBLICAÇÃO

29/07/2019

RESUMO

Abstract: Solar urticaria is a rare form of physical urticaria mediated by immunoglobulin E. The lesions appear immediately after the sun exposure, interfering with the patient's normal daily life. Omalizumab, a monoclonal anti-IgE antibody, has been recently approved for the treatment of chronic spontaneous urticaria, and the latest reports support its role also in the treatment of solar urticaria. Hereby, we report a case of solar urticaria refractory to conventional treatment strategies, with an excellent response to treatment with omalizumab and phototesting normalization.

Documentos Relacionados

• Omalizumab versus cyclosporin-A for the treatment of chronic spontaneous urticaria: can we define better-responding endotypes?
• Adverse events of the yellow fever vaccine in chronic urticaria: evaluation of patients treated or not with omalizumab compared to healthy individuals
• A Kindred with Familial Cold Urticaria: Linkage Analysis
• Chronic urticaria: profile from a reference center
• Urticaria and angioedema as possible reactions of omalizumab